| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer | 177 EAST COLORADO BLVD, SUITE 700, PASADENA | /s/James Hamilton | 05 Jan 2026 | 0001830755 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARWR | Common Stock | Sale | $283,235 | -4,625 | -2.2% | $61.24 | 207,497 | 05 Jan 2026 | Direct | F1, F2, F3, F4 |
| transaction | ARWR | Common Stock | Sale | $379,285 | -6,090 | -2.9% | $62.28 | 201,407 | 05 Jan 2026 | Direct | F1, F2, F4, F5 |
| transaction | ARWR | Common Stock | Sale | $932,044 | -14,792 | -7.3% | $63.01 | 186,615 | 05 Jan 2026 | Direct | F1, F2, F4, F6 |
| transaction | ARWR | Common Stock | Sale | $812,868 | -12,711 | -6.8% | $63.95 | 173,904 | 05 Jan 2026 | Direct | F1, F2, F4, F7 |
| transaction | ARWR | Common Stock | Sale | $77,388 | -1,200 | -0.69% | $64.49 | 172,704 | 05 Jan 2026 | Direct | F1, F2, F4, F8 |
| transaction | ARWR | Common Stock | Sale | $28,829 | -437 | -0.25% | $65.97 | 172,267 | 05 Jan 2026 | Direct | F1, F2, F4, F9 |
| transaction | ARWR | Common Stock | Sale | $21,012 | -309 | -0.18% | $68.00 | 171,958 | 05 Jan 2026 | Direct | F1, F2, F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| F2 | Partial disposition of shares to satisfy tax withholding obligations. |
| F3 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.66, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F4 | Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
| F5 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F6 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.61 to $63.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F7 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.57 to $64.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F8 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.44 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |
| F9 | The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.90 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. |